News | July 29, 2009

Congress Introduces Bill to Ensure Continuous Domestic Supplies of Medical Isotopes

July 29, 2009 – The Society of Nuclear Medicine (SNM) and a coalition of eight other organizations have issued a white paper urging Congress to take steps to maintain adequate supplies of molybdenum-99 (Mo-99), a radioactive substance that is the basis for a common medical isotope used in more than 80 percent of all nuclear medicine procedures.

The coalition jointly issued the paper to ensure that patient care is not compromised by a worldwide shortage of Mo-99 and measures to curtail the use of high-enriched uranium (HEU) in radionuclide production as a non-proliferation strategy. In response, U.S. Rep. Edward Markey (D-Mass.) introduced legislation (H.R. 3276) reflecting many of the coalition's concerns. The coalition has endorsed the legislation.

In addition to SNM, the coalition includes the American Association of Physicists in Medicine (AAPM), American College of Radiology (ACR), American Nuclear Society (ANS), American Society of Nuclear Cardiology (ASNC), American Society for Radiation Oncology (ASTRO), Council on Radionuclides and Radiopharmaceuticals (CORAR), Health Physics Society (HPS) and Nuclear Energy Institute (NEI).

"Recent closures of nuclear facilities abroad are putting a severe strain on our ability to meet demand for this critical medical isotope," said Michael Graham, M.D., Ph.D., president of SNM. "Congress should take steps to boost production domestically and to ensure that the transition away from using highly enriched uranium in medical isotope production does not further strain supplies. We applaud Congress for taking up this issue and urge the government to act without delay."

Mo-99 decays into technetium-99m (Tc-99m) – a medical isotope used in approximately 16 million nuclear diagnostic imaging procedures annually in the United States. These noninvasive procedures are essential for accurately diagnosing and treating patients with potentially life-threatening conditions such as cancer, heart disease and neurologic conditions.

Currently, more than 90 percent of Mo-99 is produced in aging nuclear reactors located in Canada, the Netherlands, Belgium, France and South Africa. Concerns about medical isotope supplies have mounted in recent years as scheduled and unplanned shutdowns of overseas reactors have interrupted production. Most recently, the National Research Universal reactor in Ontario, Canada, which supplies about 40 percent of the world's Mo-99, was shut down until later this year because of a heavy water leak following a power outage.

Further complicating the situation are recent recommendations to curtail the use of HEU in radionuclide production because of potential security concerns. However, the conversion to the alternative low-enriched uranium (LEU) to produce medical isotopes is still years away. Before such a transition can take place, large-scale commercial facilities must be planned, converted and demonstrate efficacy.

To address these concerns, the coalition's white paper recommends that the government explore a public-private partnership to speed the availability of Mo-99 and ensure continued diagnostic imaging for patients. It is imperative that domestic sources of Mo-99 be developed to guarantee a reliable supply.

The paper identifies two potential domestic sources of Mo-99 as the most viable: the University of Missouri Research Reactor Center (MURR) in Columbia, Mo., and the collaborative effort between the companies Babcock & Wilcox (B&W) and Covidien to build a reactor running strictly on LEU. MURR could meet approximately 50 percent of the U.S. demand for Mo-99 with little change, the paper notes, and it could also help fill gaps in supplies during planned shutdowns of other reactors. B&W and Covidien estimate that a new reactor technology could be operational in about five years and supply half of the U.S. demand for Mo-99. Together, these two sources could eventually meet 100 percent of the U.S. demand for Mo-99. The coalition urges the government to speed approvals for these facilities and support the Markey bill, which provides federal funding for the projects.

The organizations stress that any requirement to transition from HEU to LEU in the production of medical isotopes must ensure that supplies of Mo-99 are sufficient and that patient needs are not compromised. Adequate time must be available for research and development to guarantee that the technology and equipment are robust and reliable.

For more information: visit www.snm.org
?

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Overlay Init